{"schema_version":"secwatch.filing_event.v1","accession":"0001757898-24-000005","form_type":"8-K","ticker":"STE","cik":"0001757898","company_name":"STERIS plc","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.919048+00:00","generated_at":"2026-06-02T12:03:43.515848+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"STERIS reports FY2024 revenue up 12% to $5.5B; GAAP EPS $3.81, adjusted EPS $8.83; announces $100M restructuring plan","bullets":["Q4 revenue $1.5B (+10% YoY); Q4 GAAP net loss $1.4M (-$0.01/sh) vs $187.2M profit in prior year.","Full-year adjusted EPS grew to $8.83; constant currency organic revenue from cont. ops +10% to $5.0B.","Restructuring plan: ~$100M total charges, $44.4M recorded in Q4, balance in FY2025; $50M non-cash, $37M employee termination, $13M other.","Healthcare segment outperformed driven by US strength; CEO cites confidence in long-term growth commitments."],"urls":{"canonical":"https://secwatch.observer/filing/0001757898-24-000005","json":"https://secwatch.observer/filing/0001757898-24-000005.json","markdown":"https://secwatch.observer/filing/0001757898-24-000005.md","text":"https://secwatch.observer/filing/0001757898-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757898/000175789824000005/0001757898-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757898/000175789824000005/ste-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:03:43.515848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c9b7f5fddb1d7c341859a6c4953cbb97e4e998b","claim":"STERIS plc reported fiscal 2024 fourth quarter ended March 31, 2024 results: revenue $1.5 billion, net income ($0.01) per diluted share, EPS ($0.01) per diluted share.","evidence_excerpt":"Total revenue for the fourth quarter of fiscal 2024 increased 10% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757898/000175789824000005/0001757898-24-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 fourth quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.5 billion"},{"label":"Net income","value":"($0.01) per diluted share"},{"label":"EPS","value":"($0.01) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dcdb8c14c86fcbf800fa9d892f663e530422dee0","claim":"STERIS plc reported fiscal 2024 full year ended March 31, 2024 results: revenue $5.5 billion, net income $3.81 per diluted share, EPS $3.81 per diluted share.","evidence_excerpt":"Total revenue for fiscal 2024 increased 12% to $5.5 billion compared with $5.0 billion in fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757898/000175789824000005/0001757898-24-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 full year ended March 31, 2024"},{"label":"Revenue","value":"$5.5 billion"},{"label":"Net income","value":"$3.81 per diluted share"},{"label":"EPS","value":"$3.81 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a8780268e0fbc9e2ea21a6888f271e7d3f9de0c4","claim":"STERIS plc announced a restructuring with charges of approximately $100 million affecting Healthcare surgical business in Europe.","evidence_excerpt":"this plan to potentially impacted employees on May 7, 2024 and the restructuring is expected to be substantially completed by the end of fiscal 2025. The approximately $100 million of anticipated restructuring charges includes approximately $44.4 million recorded in the fiscal 2024 fourth quarter with the balance expected to be recorded in fiscal 2025. Of","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757898/000175789824000005/0001757898-24-000005-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $100 million"},{"label":"Affected area","value":"Healthcare surgical business in Europe"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}